Loading…
Atossa Therapeutics Inc
How the company evolved, year by year. Revenue and debt come from the annual reports — for most companies, the 10-K filings with the SEC since 2009; dividends from the payments themselves.
The bars are a balance on the closing date; the lines are what happened during the year. Revenue above equity is ordinary, not an anomaly — it means the company turns its capital over more than once a year.
Major managers that reported this stock in their latest 13F.
▼ -95.1% over 5Y.
today you would have $38.85▼ -96.1%
Dividends reinvested, splits accounted for. Past prices say what happened, not what will.
The last 14 closed years. Each multiple uses that year’s closing price and that year’s reported numbers — not today’s. The range is set by the annual reports on record.
| Indicator | Median | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Year-end price | $8.85 | $14.10 | $13.20 | $7.95 | $24.00 | $14.25 | $23.55 | $15.30 | $46.80 | $253.80 | $864.00 | $3,861.00 | $6,264.00 | $10,530.00 | |
| P/S | 509.8x | — | — | — |
Companies of similar size in Healthcare, for comparison. The columns are the same ones above, in the same order.
| Stock | Price | P/E | P/B | Dividend yield | ROE | Market cap |
|---|---|---|---|---|---|---|
| BEATHeartBeam, Inc. | $0.47 | — | 3.2x | — | -328.44% | $26.31M |
| EVAXEvaxion A/S | $3.01 | — | 2.4x | — | -109.86% | $25.1M |
| LTRNLantern Pharma Inc. | $2.07 | — | — | — | -400.92% | $26.46M |
| TXMDTherapeuticsMD, Inc. | $2.16 |
Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops medicines in areas of significant unmet medical need in oncology in the United States. Its lead drug candidate is oral (Z)-endoxifen, a selective estrogen receptor modulator and selective estrogen receptor degrader currently in Phase 2 clinical development for the treatment and reduction of risk of breast cancer, as well as in other therapeutic areas. The company was formerly known as Atossa Genetics Inc. and changed its name to Atossa Therapeutics, Inc. in January 2020. Atossa Therapeutics, Inc. was founded in 2008 and is based in Seattle, Washington.
Company description provided by Yahoo Finance.
| — |
| — |
| — |
| — |
| — |
| — |
| — |
| 7066.8x |
| 904.8x |
| 89.6x |
| 114.7x |
| P/B | 1.7x | 1.9x | 1.7x | 1.2x | 0.6x | 1.5x | 4.2x | 1.1x | 1.1x | 1.2x | 1.7x | 3.3x | 3.8x | 5.3x | 10.7x |
| EPS | -$4.04 | -$3.04 | -$3.60 | -$3.15 | -$2.70 | -$29.55 | -$30.45 | -$82.50 | -$164.55 | -$388.80 | -$1,495.80 | -$1,647.00 | -$1,890.00 | -$1,107.00 |
| Profit margin | -19111.88% | — | — | — | — | — | — | — | — | — | — | -896491.64% | -36518.83% | -1704.94% | -1054.26% |
| ROE | -99.94% | -88.35% | -35.68% | -33.06% | -22.85% | -14.92% | -65.62% | -131.04% | -129.53% | -117.06% | -205.64% | -421.20% | -154.32% | -101.73% | -98.15% |
Median, not average: a single year of near-zero profit produces a P/E of 400 and would drag an average on its own. P/E years above 200x are left out, the same cut the fair price uses — so this median matches the “its own history” method below. Price and EPS have no median: they are series that grow.
| — |
| 0.9x |
| — |
| -1.08% |
| $25M |
| FEMYFemasys Inc | $3.20 | — | 2.4x | — | -424.97% | $26.8M |
| ARAYAccuray Inc | $0.23 | — | 0.6x | — | -80.08% | $26.93M |